转移性去势抵抗性前列腺癌患者接受西普利尤赛-T单药治疗后PSA长期稳定与总生存
西普利尤赛-T是FDA批准用于无症状或轻微症状转移性去势抵抗性前列腺癌(mCRPC)的自体细胞免疫治疗,IMPACT注册试验显示4.1个月生存获益但无一致PSA反应。本研究通过单机构回顾性分析及4家泌尿外科集团实践的336例患者中44例符合标准者,发现79%(95% CI: 64.5%, 88.1%)生存36个月,中位至后续治疗时间17.8个月(95% CI 10.3, 25.3)。
要点
- IMPACT试验显示西普利尤赛-T有4.1个月生存获益但无一致PSA反应。
- 44例符合标准患者中79%生存36个月,中位至后续治疗17.8个月。
- 作者认为数据支持在特定mCRPC患者中单用西普利尤赛-T。
核心结论
- 尽管患者选择可能解释部分或全部结果,这些数据支持在特定mCRPC患者中使用西普利尤赛-T单药,与疾病进展延迟和良好总体预后相关。
研究设计与样本
- 单机构回顾性分析mCRPC患者接受西普利尤赛-T和持续ADT治疗,并识别长期疾病控制且无额外干预的亚组。
- 评估2010年至2014年间4家大型泌尿外科集团实践中336例接受西普利尤赛-T治疗的患者,识别44例符合相同标准且显示PSA稳定证据者。
主要发现
- 该亚组患者中79%(95% CI: 64.5%, 88.1%)生存36个月。
- 中位至后续治疗时间为17.8个月(95% CI 10.3, 25.3)。
临床怎么用
- 作者认为数据支持在特定mCRPC患者中单用西普利尤赛-T,与疾病进展延迟和良好总体预后相关。
局限性
- 患者选择可能解释部分或全部结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sipuleucel-T is an autologous cellular immunotherapy that is FDA approved for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC). The IMPACT registry trial demonstrated a 4.1 month survival benefit, but not a consistent PSA response or improvement in progression-free survival. Based upon several factors, including this lack of objective treatment response, sipuleucel-T has been under-utilized in this patient population, despite current NCCN recommendations. METHODS: In order to explore if delayed treatment response occurs in a subset of patients, we performed a single institutional retrospective analysis of mCRPC patients treated with sipuleucel-T and ongoing ADT alone. Within that group, we then identified a subset of sipuleucel-T-treated men with long-term disease control and no additional interventions. To independently confirm this finding, we evaluated a total of 336 patients from 4 large urology group practices treated with sipuleucel-T between 2010 and 2014 and identified 44 patients who met the same criteria and demonstrated evidence of PSA stabilization post sipuleucel-T treatment. RESULTS: For this subgroup of patients, 79% (95% CI: 64.5%, 88.1%) survived 36 months with a median time to subsequent therapy of 17.8 months (95% CI 10.3, 25.3). CONCLUSIONS: Although patient selection could account for some or all of these results, these data support the utilization of sipuleucel-T alone in select mCRPC patients that is associated with a delay in disease progression and a good overall prognosis.
引用
- Holl EK, McNamara MA, Healy P, et al. Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients. Prostate Cancer Prostatic Dis. 2019. PMID: 30980027. doi:10.1038/s41391-019-0144-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。